Brief: Bioxcel Therapeutics Announces 33% Enrollment In Serenity At-Home Pivotal Phase 3 Safety Trial
07/03/2025 12:01
March 7 (Reuters) - BioXcel Therapeutics Inc BTAI.O: BIOXCEL THERAPEUTICS ANNOUNCES 33% ENROLLMENT IN SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA BIOXCEL THERAPEUTICS INC: TOPLINE DATA EXPECTED IN SECOND HALF OF 2025 BIOXCEL THERAPEUTICS: SERENITY PHASE 3 SAFETY TRIAL TOPLINE DATA EXPECTED IN H2 2025 Source text: ID:nGNX305GcS Further company coverage: BTAI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty